Normothermic Regional Perfusion Policy

Background

Normothermic regional perfusion (NRP) is a technique that restores warm, oxygen-rich blood flow to selected organs after death has been declared to help preserve them for transplantation.

In September 2024, HRSA directed the OPTN to investigate potential policy violations related to NRP and develop standards to protect patients and improve donor families’ experiences.

The OPTN Board of Directors approved the NRP Policy through an emergency action so urgent safety safeguards could take effect immediately, with additional requirements implemented in phases. The policy will still undergo public comment and may be updated based on feedback.

Sponsors: OPTN Board of Directors and NRP Workgroup
Public Comment Period: Nov. 13 - Dec. 28, 2026 
Board Approved: TBD
Effective Date: Phased implementation as outlined below

Submit a comment

Summary of policy changes

The Board-approved policy establishes new and enhanced safeguards for patient safety, authorization and disclosure, communication, and accountability. It:

  • Clarifies and reorganizes required steps for organ procurement organizations (OPOs) to better reflect the stages of the organ donation and procurement process.
  • Strengthens the information that must be disclosed to donors or their agents.
  • Establishes requirements for using NRP in controlled donation after circulatory death (DCD).
  • Adds reporting requirements for NRP procedure details and any potential patient safety events.

Phased implementation

Implementation begins immediately, with requirements taking effect in phases to prioritize urgent safety protections and allow time for operational changes needed to support additional requirements.

Phase 1 (tentatively 30 days after Board approval)

Surgical techniques

  • NRP must not begin until after 5 minutes have elapsed after pulselessness and the donor is pronounced dead by the hospital patient care team
  • The NRP team must take all necessary steps to prevent blood flow to the brain (secure, transect, and vent blood vessels at risk of perfusing the brain)
  • Paralytic agents must not be used in the context of NRP

Routine documentation

  • For all actual/attempted recoveries using NRP, OPO must upload DCD flowsheet and operative note within 24 hours (requirement expands to include documentation of pre-withdrawal huddle when this is implemented)

Reporting requirements for patient safety events

  • Reportable events: (1) Pre-mortem cannulation is performed and the patient’s death does not occur within the expected time frame; (2) An unplanned pause is requested due to concern that perfusion may have been restored to the brain.
  • Reportable events: There is withdrawal of life-sustaining support prior to the pre-recovery huddle

Phase 2 (tentatively 3-6 months after public comment)

Communication requirements

  • Pre-departure huddle:
    • Includes OPO representative and lead surgeons from procurement and NRP teams
    • Participants review surgical approach and verify surgical team members who will be present
  • Prior to withdrawal of life sustaining therapy (WLST) huddle:
    • Includes OPO staff, donor hospital operating room staff, surgical procurement team, and NRP team
    • Participants (1) review how to raise concerns, how to initiate an unplanned pause, surgical approach; and (2) confirm plan for how patient care will be transferred back to the hospital healthcare team if a concern is raised

Authorization requirements

  • Pre-mortem procedures (e.g., cannulation) require consent of the donor or donor’s agent
  • OPOs may have a separate authorization form for NRP or include NRP authorization in their standard authorization form for organ donation
  • Disclosures regarding NRP must include the following information:
    • NRP is performed to increase the likelihood that the organs will be utilized for transplant
    • NRP restores perfusion to certain organs, and those organs are expected to resume function
    • There is a potential risk of restoring blood flow to the donor’s brain; the team will make every effort to prevent this from happening

Documentation of plan to return donor to the care of the hospital

  • OPOs must have a documented plan for how patient care will be transferred back to the hospital healthcare team if concerns arise for cerebral perfusion or other physical responses during the NRP process

The OPTN will provide implementation notices, guidance, and educational resources to help members meet the requirements as each phase takes effect.

Resources

*If you use assistive technology, you may not be able to access information in these files. For help, contact us at 800-221-9393.

Questions for Consideration

The Workgroup welcomes community feedback on all aspects of the proposal and offers the following questions for consideration: 

  • The OPTN policies reference the term “time of cross-clamp” in OPTN Policy 2.15.D.i Process for a Pause. Clamp time is defined on the OPTN website as “The time at which the flow of blood to a particular organ has been clamped off during a procurement.” Is this definition sufficient and aligned appropriately with the intentions of NRP policy?
  • OPTN Members are responsible for complying with all OPTN Obligations, per OPTN Management and Membership Policy F.1.e Member Compliance, which include acting to avoid risks to patient health or public safety. Do you agree that policy should specify the following: In the event that there are questions about whether the potential donor is exhibiting signs of life, OPO providers and relevant staff must remain in the room until the patient care team is available to receive patient hand-off. 
  • Do the potential metrics of interest in Exhibit 1 adequately capture initiation and stoppage of NRP? What additional metrics should the OPTN consider monitoring at the time on circuit for NRP? How can the OPTN monitor that action is taken to halt NRP “without delay” or “within a short period of time” when signs of life are observed during the NRP process?

Public comments open

The public may submit comments on this policy proposal from November 13 through December 28, 2026. HRSA staff will review the comments and post them on this page within two to three business days.  

Date Last Reviewed:

Submit a Comment

Public Comment

  • Allowed HTML tags: <br> <p class="text-align-left text-align-center text-align-right text-align-justify"> <h2 class="text-align-left text-align-center text-align-right text-align-justify"> <h3 class="text-align-left text-align-center text-align-right text-align-justify"> <h4 class="text-align-left text-align-center text-align-right text-align-justify"> <h5 class="text-align-left text-align-center text-align-right text-align-justify"> <h6 class="text-align-left text-align-center text-align-right text-align-justify"> <strong> <b> <em> <u> <s> <sub> <sup> <blockquote> <ul> <ol reversed start> <li> <hr>
  • Lines and paragraphs break automatically.
Alexis Pratt 11/14/2026

Subject: Public Comment on Normothermic Regional Perfusion (NRP) Policy — Violation of Donor Trust and Dignity

Hello,

As a registered organ donor, I am writing to express my strong opposition to Normothermic Regional Perfusion (NRP) and the lack of transparent, upfront informed consent surrounding it.

Signing up as an organ donor is an act of trust—a willingness to give a gift after death, not consent to have circulation restarted, major blood vessels surgically vented or clamped, or my body treated as an organ-preservation machine.

Learning that procurement agencies are normalizing these invasive procedures without explicit, individual authorization from donors is deeply disrespectful, cruel, and inhumane.

Treating donors as biological reservoirs rather than patients deserving of dignity from beginning to end destroys public trust.

Upon learning about these protocols, my immediate reaction was to look up how to immediately revoke my donor registration entirely.

If the OPTN and procurement organizations continue prioritizing organ extraction over basic human dignity and explicit donor consent, they will drive away willing donors and worsen the very shortage they claim to solve.

At an ABSOLUTE BARE MINIMUM NRP must be strictly prohibited unless a donor has explicitly opted into that specific procedure in advance. A blanket checkmark on a driver's license cannot and must not be treated as consent for NRP.

Anonymous 11/14/2026

I work on the OPO side as a procurement coordinator and am involved in setting up pre-OR NRP huddles. I think that the requirements for NRP huddles is a good thing to have in policy. I do find that there are always issues with getting these set up at a time that works for all involved parties. Adding this requirement to policy will hopefully help with getting all members into the huddle. Adding those comments to the NRP consent document it a good idea, so families are better informed of the very unknown procedure.
I have no negative comments about these changes.

Luke Boganny, CCP 11/13/2026

I would like to see language that ensures that every aspect of NRP is performed by appropriately qualified professionals such as certified perfusionists with the operation of the NRP equipment and surgeons who are accountable to the highest standards of clinical practice, patient safety, professional ethics, and operational excellence. This commitment is essential to protecting the interests of donors, recipients, transplant centers, Organ Procurement Organizations (OPOs), and all other stakeholders while ensuring the highest possible quality of care and integrity throughout the organ recovery process.

Anonymous 11/13/2026

Regarding the pre-departure huddle: due to the demands of healthcare teams and the unique demands of procurement/transplant providers, it's challenging to find a date-time that will work for all involved, transplant providers understanding the importance of these communications and puts the ownness of non-OPO members to adhere to OPO policies. It's more feasible for these communications to occur once all parties arrive to the procurement site. Additionally, often times the previously dedicated procurement personnel change and the OPO is not made aware of the change in personnel until they arrive to the procurement site.

Adam Omelianchuk, PhD, MA 11/13/2026

Comment on OPTN's Proposed Normothermic Regional Perfusion (NRP) Policy

I appreciate the effort that the OPTN has invested in developing a policy for NRP. The proposed policy contains important procedural safeguards (e.g. the 5-minute waiting time) and reflects a serious attempt to standardize practice (venting, huddling, etc.). Nevertheless, I remain concerned that the proposal does not adequately address several issues essential to maintaining public trust in deceased organ donation: legal clarity regarding death determination, adequate disclosure with the option to refuse, and the management of conflicts of interest.

First, the proposal states that NRP is initiated only after death has been declared but the meaning of “death” is not clear in this proposal. The proposal recognizes that “perfusion” is restored to selected organs, but the restoration of “perfusion” cannot occur without the restoration of circulation. Yet, per state and federal law, the cessation of “circulatory and respiratory functions” is to be at least permanent (i.e., the Uniform Determination of Death Act, UDDA). I noted on page 16 of 23 that “circulation” was replaced with “perfusion.” Are these supposed to be two different things? How are they related? This shift in language betrays a lack of clarity in terms of how the Workgroup interprets “circulatory and respiratory function” which are key aspects of federal and local laws that govern donation after circulatory determination of death protocols. Substituting “perfusion” for “circulation” does not explain how either form of NRP remain consistent with the legal standards for the declaration of death in the first place. The policy appears to assume a particular interpretation of death determination without providing a legal rationale for it. Given the public importance of this issue, OPTN should not treat the compatibility of NRP with prevailing standards for determining death as a given or a question beyond the scope of its policy development. Rather, it should explain the legal interpretation of the UDDA and relevant statutes on which the policy rests and why that interpretation justifies the practice.

Second, the proposed disclosure requirements do not adequately support “informed” authorization, nor do they provide an opportunity for NRP to be refused. As I have already noted, the policy requires disclosure that “perfusion” but not “circulation” is restored. However, the choice of “perfusion” is not consistent with the requirement to communicate in plain language. Nor does it convey that reasonable disagreement exists regarding the interpretation of a “circulatory determination of death” on which NRP depends. More importantly, it is not clear whether families are being “asked” or “told” about NRP. Can they decline it after being informed of its aspects? Whatever the case may be, meaningful “informed authorization” requires not only disclosure of what will occur physiologically, but also disclosure of the assumptions used to explain why those interventions are considered ethically and legally permissible under local and federal determination of death statutes.

Third, the proposal does not sufficiently address concerns regarding conflicts of interest. Recent guidance from CMS on Clinical Standards and Quality for OPOs emphasizes the importance of maintaining clear separation between organ procurement organizations, end-of-life decision-making, withdrawal of life-sustaining treatment, and death determination. The rationale for these safeguards is straightforward: the professionals responsible for caring for dying patients should be different from those whose mission is organ recovery. Preserving that separation has long been central to public trust in organ donation.

Yet the proposed NRP policy places substantial burdens of responsibility on the procurement team to monitor conditions that could compromise donor safety, including failure of measures intended to prevent cerebral reperfusion and the appearance of “signs of life.” The very existence of these responsibilities betrays the ethical significance of the interventions being performed. If monitoring for signs of life or possible restoration of brain circulation is necessary to discharge duties of safety for the donor-patient, the responsibility for oversight should be assumed by clinicians (preferably an attending physician) whose primary duty is to the donor-patient, not by individuals whose responsibility is organ recovery. OPTN should strengthen the firewall between treatment and procurement functions and clarify that responsibility for donor assessment and neuromonitoring resides with independent clinical personnel. This would render moot the question about whether the procurement team should stay with the patient if “signs of life” are observed and it would more adequately manage the conflict-of-interest procurement team faces.

For these reasons, OPTN should go beyond stipulating procedural safeguards and revise the policy to provide a clearer explanation of why it thinks NRP is consistent with legal standards for a circulatory determination of death, strengthen the disclosure requirements, clarify whether NRP can be declined by those to whom disclosure is given, and reinforce protections against conflicts of interest. Doing so would better protect donors, support families, and preserve public confidence in the transplant system.

Sincerely,

Adam Omelianchuk, PhD, MA